About EsoBiotec
EsoBiotec is a company based in Mont-saint-guibert (Belgium) founded in 2020 by Jean-Pierre Latere was acquired by Astrazeneca in March 2025. EsoBiotec has raised $2.15 million across 2 funding rounds from investors including Astrazeneca, Invivo Partners and UCB Ventures. The company has 8 employees as of December 31, 2022. EsoBiotec offers products and services including ENaBL Vector Platform and Off-the-Shelf Therapies. EsoBiotec operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Poseida Therapeutics, among others.
- Headquarter Mont-saint-guibert, Belgium
- Employees 8 as on 31 Dec, 2022
- Founders Jean-Pierre Latere
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Esobiotec
-
Annual Revenue
Not available
-
Net Profit
-$1.06 M (USD)-406as on Dec 31, 2022
-
EBITDA
$1.53 M (USD)898as on Dec 31, 2022
-
Total Equity Funding
$2.15 M (USD)
in 2 rounds
-
Latest Funding Round
$2.15 M (USD), Series A
Dec 11, 2023
-
Investors
Astrazeneca
& 5 more
-
Employee Count
8
as on Dec 31, 2022
-
Acquired by
Astrazeneca
(Mar 17, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EsoBiotec
EsoBiotec offers a comprehensive portfolio of products and services, including ENaBL Vector Platform and Off-the-Shelf Therapies.
Enables in vivo cell therapies for cancer treatment and disease management.
Provides immune-shielded treatments for solid tumors and autoimmune conditions.
Funding Insights of EsoBiotec
EsoBiotec has successfully raised a total of $2.15M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.15 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EsoBiotec
EsoBiotec has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, Invivo Partners and UCB Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Invivo Partners is engaged in venture capital investments for early-stage healthcare companies.
|
Locked | Locked | Locked | |
|
UCB Ventures is focused on strategic corporate venture investments.
|
Locked | Locked | Locked | |
|
Early-stage centric life sciences focused VC firm funding in Netherlands, Belgium and the US
|
Locked | Locked | Locked |
Investor details for EsoBiotec
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EsoBiotec
Investment portfolio details for EsoBiotec
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EsoBiotec
Detailed financials for EsoBiotec
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Esobiotec Comparisons
Peer comparison for EsoBiotec
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EsoBiotec
EsoBiotec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Poseida Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
Detailed competitors of EsoBiotec
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Esobiotec
Complete news archive for EsoBiotec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EsoBiotec
EsoBiotec was founded in 2020 and raised its 1st funding round 1 year after it was founded.
EsoBiotec is headquartered in Mont-saint-guibert, Belgium.
Jean-Pierre Latere is the current CEO of EsoBiotec. They have also founded this company.
EsoBiotec is a funded company, having raised a total of $2.15M across 2 funding rounds to date.
As of Dec 31, 2022, the latest employee count at EsoBiotec is 8.
EsoBiotec was founded in 2020 within the biotechnology sector, where in vivo adoptive cell therapies for cancer and autoimmune diseases are developed. Immune cells are engineered directly in patients to avoid ex vivo manufacturing complexities. A proprietary vector platform is employed for single-injection, off-the-shelf treatments that minimize rejection risks and enable scalable, high-yield production. Operations focus on simplifying logistics and improving accessibility through reduced costs.
EsoBiotec's top competitors include Moderna, BeiGene and Juno Therapeutics.
EsoBiotec offers ENaBL Vector Platform and Off-the-Shelf Therapies.
EsoBiotec has 6 investors. Key investors include Astrazeneca, Invivo Partners, UCB Ventures, Thuja Capital, and Sambrinvest.